Sumitomo Dainippon Pharma, dainippon sumitomo pharma.#Dainippon #sumitomo #pharma

Posted On Feb 28 2018 by

dainippon sumitomo pharma What’s New News Releases Nov. 21, 2017 (PDF/252KB)Licensing Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe Nov. 13, 2017 (PDF/206KB)R ?>


Profiles of Major Products under Development, Clinical Development, Research and Development, Sumitomo Dainippon Pharma, dainippon sumitomo pharma.#Dainippon #sumitomo #pharma

Posted On Jan 15 2018 by

Profiles of Major Products *as of October 30, 2017 LATUDA В® (lurasidone hydrochloride)гЂЂAtypical antipsychotic Developed in-house LATUDA В® (lurasidone hydrochloride) is an atypical antipsychotic agent that is believed to have an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, LATUDA is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine H1 or muscarinic M1 receptors. Approved country and area: Schizophrenia 2010: U.S., 2012: Canada, 2013: Switzerland, 2014: Europe and Australia, 2016: Taiwan, Russia, Singapore, Thailand and Hong Kong, 2017: Brazil Bipolar I depressionгЂЂ 2013: U.S., …